JP2002526410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002526410A5 JP2002526410A5 JP2000573362A JP2000573362A JP2002526410A5 JP 2002526410 A5 JP2002526410 A5 JP 2002526410A5 JP 2000573362 A JP2000573362 A JP 2000573362A JP 2000573362 A JP2000573362 A JP 2000573362A JP 2002526410 A5 JP2002526410 A5 JP 2002526410A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylcarbamoyl
- cyano
- hydrogen
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 8
- 125000004093 cyano group Chemical group *C#N 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 150000002431 hydrogen Chemical class 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 125000005236 alkanoylamino group Chemical group 0.000 description 4
- 125000001589 carboacyl group Chemical group 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- -1 hydroxy, methoxycarbonyl Chemical group 0.000 description 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000035873 hypermotility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9821703.7 | 1998-10-07 | ||
| GBGB9821703.7A GB9821703D0 (en) | 1998-10-07 | 1998-10-07 | Compounds |
| GBGB9905238.3A GB9905238D0 (en) | 1999-03-09 | 1999-03-09 | Compounds |
| GB9905238.3 | 1999-03-09 | ||
| PCT/GB1999/003273 WO2000020003A1 (en) | 1998-10-07 | 1999-10-04 | Naphthalenecarboxamides as tachykinin receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002526410A JP2002526410A (ja) | 2002-08-20 |
| JP2002526410A5 true JP2002526410A5 (enExample) | 2006-11-24 |
Family
ID=26314462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000573362A Pending JP2002526410A (ja) | 1998-10-07 | 1999-10-04 | タキキニン受容体拮抗剤としてのナフタレンカルボキシアミド |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6500818B1 (enExample) |
| EP (1) | EP1119355B1 (enExample) |
| JP (1) | JP2002526410A (enExample) |
| KR (1) | KR20010099674A (enExample) |
| CN (1) | CN1322134A (enExample) |
| AT (1) | ATE230598T1 (enExample) |
| AU (1) | AU6111099A (enExample) |
| BR (1) | BR9914333A (enExample) |
| CA (1) | CA2344807A1 (enExample) |
| DE (1) | DE69904847T2 (enExample) |
| GB (1) | GB9922519D0 (enExample) |
| ID (1) | ID25749A (enExample) |
| IL (1) | IL142048A0 (enExample) |
| NO (1) | NO20011766L (enExample) |
| WO (1) | WO2000020003A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6903092B2 (en) | 2000-04-06 | 2005-06-07 | Peter Bernstein | Naphthamide neurokinin antagonists for use as medicaments |
| DE60134735D1 (de) * | 2000-04-06 | 2008-08-21 | Astrazeneca Ab | Neue neurokinin-antagonisten zum gebrauch als arzneimittel |
| WO2001077069A1 (en) * | 2000-04-06 | 2001-10-18 | Astrazeneca Ab | Naphthamide neurokinin antagonists for use as medicaments |
| US6846814B2 (en) | 2000-04-06 | 2005-01-25 | Astra Zeneca Ab | Neurokinin antagonists for use as medicaments |
| GB0015246D0 (en) * | 2000-06-22 | 2000-08-16 | Astrazeneca Ab | Method for the treatment of urinary incontinence |
| SE0004827D0 (sv) | 2000-12-22 | 2000-12-22 | Astrazeneca Ab | Therapeutic compounds |
| SE0103795D0 (sv) * | 2001-11-02 | 2001-11-02 | Astrazeneca Ab | Compounds and method for the treatment of överactive bladder |
| SE0103668D0 (sv) * | 2001-11-02 | 2001-11-02 | Astrazeneca Ab | Method for the treatment of overactive blader |
| SE0201938D0 (sv) * | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New process |
| FR2853648B1 (fr) * | 2003-04-11 | 2006-08-18 | Fournier Lab Sa | Nouveaux derives de benzenesulfonamides et leur utilisation en therapeutique |
| TW200508221A (en) | 2003-06-13 | 2005-03-01 | Astrazeneca Ab | New azetidine compounds |
| SE0403005D0 (sv) * | 2004-12-09 | 2004-12-09 | Astrazeneca Ab | New use |
| EP1899318A4 (en) * | 2005-06-23 | 2010-03-17 | Astrazeneca Ab | NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF STOMACH DARM DISEASES |
| WO2006137790A1 (en) * | 2005-06-23 | 2006-12-28 | Astrazeneca Ab | New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases |
| AR057828A1 (es) | 2005-09-29 | 2007-12-19 | Astrazeneca Ab | Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica |
| AR056087A1 (es) * | 2005-09-29 | 2007-09-19 | Astrazeneca Ab | Derivados de azetidina como antagonistas de receptores de neuroquina nk |
| JP2009525308A (ja) * | 2006-02-01 | 2009-07-09 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規のｎｋ２／ｎｋ３−デュアルアンタゴニスト、それらを含有する医薬組成物並びにそれらの製造方法 |
| US8106208B2 (en) | 2006-05-18 | 2012-01-31 | Albireo Ab | Benzamide compounds that act as NK receptor antagonists |
| EP2117538A1 (en) | 2007-01-24 | 2009-11-18 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| EP2364082A4 (en) | 2008-10-21 | 2012-06-06 | Oregon Health And Sciences University | NAPHTHAMIDE AS ANTICROBIAL |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE903957A1 (en) * | 1989-11-06 | 1991-05-08 | Sanofi Sa | Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present |
| IL99320A (en) * | 1990-09-05 | 1995-07-31 | Sanofi Sa | Arylalkylamines, their preparation and pharmaceutical compositions containing them |
| FR2676054B1 (fr) | 1991-05-03 | 1993-09-03 | Sanofi Elf | Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2688219B1 (fr) | 1992-03-03 | 1994-07-08 | Sanofi Elf | Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant. |
| GB9310713D0 (en) | 1993-05-24 | 1993-07-07 | Zeneca Ltd | Aryl substituted heterocycles |
-
1999
- 1999-09-24 GB GBGB9922519.5A patent/GB9922519D0/en not_active Ceased
- 1999-10-04 US US09/806,620 patent/US6500818B1/en not_active Expired - Fee Related
- 1999-10-04 DE DE69904847T patent/DE69904847T2/de not_active Expired - Fee Related
- 1999-10-04 EP EP99947737A patent/EP1119355B1/en not_active Expired - Lifetime
- 1999-10-04 CA CA002344807A patent/CA2344807A1/en not_active Abandoned
- 1999-10-04 BR BR9914333-0A patent/BR9914333A/pt not_active IP Right Cessation
- 1999-10-04 CN CN99811925A patent/CN1322134A/zh active Pending
- 1999-10-04 JP JP2000573362A patent/JP2002526410A/ja active Pending
- 1999-10-04 KR KR1020017004355A patent/KR20010099674A/ko not_active Withdrawn
- 1999-10-04 WO PCT/GB1999/003273 patent/WO2000020003A1/en not_active Ceased
- 1999-10-04 IL IL14204899A patent/IL142048A0/xx unknown
- 1999-10-04 AU AU61110/99A patent/AU6111099A/en not_active Abandoned
- 1999-10-04 AT AT99947737T patent/ATE230598T1/de not_active IP Right Cessation
- 1999-10-06 ID IDP990929D patent/ID25749A/id unknown
-
2001
- 2001-04-06 NO NO20011766A patent/NO20011766L/no not_active Application Discontinuation